Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 53, Issue 12

Issues

Considerations in parathyroid hormone testing

Etienne Cavalier / Mario Plebani / Pierre Delanaye
  • Department of Nephrology, Dialysis and Transplantation, University of Liège, CHU Sart-Tilman, Liège, Belgium
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Jean-Claude Souberbielle
Published Online: 2015-06-02 | DOI: https://doi.org/10.1515/cclm-2015-0314

Abstract

Parathyroid hormone (PTH) is a major player in phosphocalcic metabolism and its measurement is very important for the correct diagnosis and treatment of several diseases. PTH determination represents the paradigm of quality in laboratory medicine as many variables in the pre-, intra-, and post-analytical phases strongly affect the value of the clinical information. Analytical determination of PTH has been rendered difficult by the presence, in the circulation, of truncated fragments that can cross-react with the antibodies used for its determination. In addition, pre-analytical phase is complicated by the lack of stability of the peptide and the best sample to use for its determination remains controversial, as well as sample handling and storage. PTH secretion is also affected by circadian and seasonal rhythms and by physical exercise. Finally, from the post-analytical perspective, establishment of reliable reference ranges requires further efforts as the selection criteria for reference subjects should take into consideration new variables such as gender, race and vitamin D levels. Finally, clinical guidelines have recently revised and improved the criteria for a correct interpretation of PTH values.

Keywords: calcium metabolism; clinical guidelines; diurnal and seasonal rhythms; parathyroid hormone; reference ranges; sample of choice; stability

References

  • 1.

    Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int 2010;77:93–100.PubMedCrossrefGoogle Scholar

  • 2.

    Naylor SL, Sakaguchi AY, Szoka P, Hendy GN, Kronenberg HM, Rich A, et al. Human parathyroid hormone gene (PTH) is on short arm of chromosome 11. Somatic Cell Genet 1983;9:609–16.CrossrefGoogle Scholar

  • 3.

    Ramasamy I. Inherited disorders of calcium homeostasis. Clin Chim Acta 2008;394:22–41.CrossrefPubMedGoogle Scholar

  • 4.

    Juppner H, bou-Samra AB, Freeman M, Kong XF, Schipani E, Richards J, et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991;254:1024–6.CrossrefGoogle Scholar

  • 5.

    Gardella TJ, Axelrod D, Rubin D, Keutmann HT, Potts JT Jr., Kronenberg HM, et al. Mutational analysis of the receptor-activating region of human parathyroid hormone. J Biol Chem 1991;266:13141–6.PubMedGoogle Scholar

  • 6.

    Pfister MF, Ruf I, Stange G, Ziegler U, Lederer E, Biber J, et al. Parathyroid hormone leads to the lysosomal degradation of the renal type II Na/Pi cotransporter. Proc Natl Acad Sci USA 1998;95:1909–14.CrossrefGoogle Scholar

  • 7.

    Segre GV, Perkins AS, Witters LA, Potts J Jr. Metabolism of parathyroid hormone by isolated rat Kupffer cells and hepatocytes. J Clin Invest 1981;67:449–57.CrossrefPubMedGoogle Scholar

  • 8.

    Hilpert J, Nykjaer A, Jacobsen C, Wallukat G, Nielsen R, Moestrup SK, et al. Megalin antagonizes activation of the parathyroid hormone receptor. J Biol Chem 1999;274:5620–5.PubMedCrossrefGoogle Scholar

  • 9.

    D’Amour P, Brossard JH. Carboxyl-terminal parathyroid hormone fragments: role in parathyroid hormone physiopathology. Curr Opin Nephrol Hypertens 2005;14:330–6.PubMedCrossrefGoogle Scholar

  • 10.

    Bringhurst FR. Circulating forms of parathyroid hormone: peeling back the onion. Clin Chem 2003;49:1973–5.PubMedGoogle Scholar

  • 11.

    Singh RJ, Hines JM, Lopez MF, Krastins B, Hoofnagle AN. Mass spectrometric immunoassay raises doubt for the existence of parathyroid hormone fragment 7-84. Clin Chem 2015;61: 558–60.PubMedGoogle Scholar

  • 12.

    Rubin MR, Silverberg SJ, D’Amour P, Brossard JH, Rousseau L, Sliney J Jr., et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem 2007;53:1470–6.CrossrefGoogle Scholar

  • 13.

    Caron P, Maiza JC, Renaud C, Cormier C, Barres BH, Souberbielle JC. High 3(rd) generation/2(nd) generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of 3(rd) generation/2(nd) generation PTH ratio in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 2009;70: 533–8.CrossrefGoogle Scholar

  • 14.

    Rakel A, Brossard JH, Patenaude JV, Albert C, Nassif E, Cantor T, et al. Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol (Oxf) 2005;62:721–7.CrossrefGoogle Scholar

  • 15.

    Frelinger AL, III, Zull JE. Oxidized forms of parathyroid hormone with biological activity. Separation and characterization of hormone forms oxidized at methionine 8 and methionine 18. J Biol Chem 1984;259:5507–13.Google Scholar

  • 16.

    Hocher B, Oberthur D, Slowinski T, Querfeld U, Schaefer F, Doyon A, et al. Modeling of oxidized PTH (oxPTH) and non-oxidized PTH (n-oxPTH) receptor binding and relationship of oxidized to non-oxidized PTH in children with chronic renal failure, adult patients on hemodialysis and kidney transplant recipients. Kidney Blood Press Res 2013;37:240–51.PubMedCrossrefGoogle Scholar

  • 17.

    Tepel M, Armbruster FP, Gron HJ, Scholze A, Reichetzeder C, Roth HJ, et al. Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients. J Clin Endocrinol Metab 2013;98:4744–51.PubMedCrossrefGoogle Scholar

  • 18.

    Hocher B, Armbruster FP, Stoeva S, Reichetzeder C, Gron HJ, Lieker I, et al. Measuring parathyroid hormone (PTH) in patients with oxidative stress – do we need a fourth generation parathyroid hormone assay? PLoS One 2012;7:e40242.CrossrefGoogle Scholar

  • 19.

    WHO. Use of anticoagulants in diagnostic laboratory investigations and stability of blood, plasma and serum samples. WHO. 2002.Google Scholar

  • 20.

    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD work group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;6:S1–130.Google Scholar

  • 21.

    Cavalier E, Souberbielle JC, Gadisseur R, Dubois B, Krzesinski JM, Delanaye P. Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients. Clin Biochem 2014;47: 1227–30.PubMedCrossrefGoogle Scholar

  • 22.

    Scharnhorst V, Valkenburg J, Vosters C, Vader H. Influence of preanalytical factors on the immulite intact parathyroid hormone assay. Clin Chem 2004;50:974–5.CrossrefPubMedGoogle Scholar

  • 23.

    Hanon EA, Sturgeon CM, Lamb EJ. Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review. Clin Chem Lab Med 2013;51:1925–41.PubMedCrossrefGoogle Scholar

  • 24.

    Teal TK, Wood JL, Stevens PE, Lamb EJ. Stability of Bio-Intact (1-84) parathyroid hormone ex vivo in serum and EDTA plasma from hemodialysis patients. Clin Chem 2004;50:1713–4.CrossrefPubMedGoogle Scholar

  • 25.

    Morales Garcia AI, Gorriz Teruel JL, Plancha Mansanet MC, Escudero QV, Pallardo Mateu LM. Analysis of variability in determining intact parathyroid hormone (iPTH) according to the method used to process the sample. Nefrologia 2009;29:331–5.PubMedGoogle Scholar

  • 26.

    Parent X, Alenabi F, Brignon P, Souberbielle JC. [Delayed measurement of PTH in patients with CKD: storage of the primary tube in the dialysis unit, which temperature? Which kind of tube?]. Nephrol Ther 2009;5:34–40.PubMedCrossrefGoogle Scholar

  • 27.

    Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008;51:987–95.PubMedCrossrefGoogle Scholar

  • 28.

    Jane EM, Livesey JH, Evans MJ. Hormone stability in human whole blood. Clin Biochem 2003;36:109–12.CrossrefGoogle Scholar

  • 29.

    Parent X, Alenabi F, Etienne E, Brignon P, Chantrel F, Meynaud-Kraemer L. Preanalytical variability of parathyroid hormone measurement in dialysis patients; application to Elecsys 2010 (Roche) automate. Ann Biol Clin (Paris) 2008;66:53–8.Google Scholar

  • 30.

    Evans MJ, Livesey JH, Ellis MJ, Yandle TG. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem 2001;34:107–12.PubMedCrossrefGoogle Scholar

  • 31.

    Ratcliffe WA, Heath DA, Ryan M, Jones SR. Performance and diagnostic application of a two-site immunoradiometric assay for parathyrin in serum. Clin Chem 1989;35:1957–61.PubMedGoogle Scholar

  • 32.

    Stokes FJ, Ivanov P, Bailey LM, Fraser WD. The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism. Clin Chem 2011;57:138–40.PubMedCrossrefGoogle Scholar

  • 33.

    Zwart SR, Wolf M, Rogers A, Rodgers S, Gillman PL, Hitchcox K, et al. Stability of analytes related to clinical chemistry and bone metabolism in blood specimens after delayed processing. Clin Biochem 2009;42:907–10.CrossrefPubMedGoogle Scholar

  • 34.

    Oddoze C, Lombard E, Portugal H. Stability study of 81 analytes in human whole blood, in serum and in plasma. Clin Biochem 2012;45:464–9.PubMedCrossrefGoogle Scholar

  • 35.

    Cavalier E, Delanaye P, Hubert P, Krzesinski JM, Chapelle JP, Rozet E. Estimation of the stability of parathyroid hormone when stored at -80 degrees C for a long period. Clin J Am Soc Nephrol 2009;4:1988–92.PubMedCrossrefGoogle Scholar

  • 36.

    Cavalier E, Carlisi A, Bekaert AC, Rousselle O, Chapelle JP, Delanaye P. New insights on the stability of the parathyroid hormone as assayed by an automated 3rd generation PTH assay. Clin Chim Acta 2012;413:353–4.CrossrefGoogle Scholar

  • 37.

    Holmes DT, Levin A, Forer B, Rosenberg F. Preanalytical influences on DPC IMMULITE 2000 intact PTH assays of plasma and serum from dialysis patients. Clin Chem 2005;51:915–7.CrossrefGoogle Scholar

  • 38.

    Gardham C, Stevens PE, Delaney MP, LeRoux M, Coleman A, Lamb EJ. Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol 2010;5:1261–7.PubMedCrossrefGoogle Scholar

  • 39.

    Cavalier E, Delanaye P, Moranne O. Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis 2013;61:847–8.PubMedCrossrefGoogle Scholar

  • 40.

    ISO 5725-6. Accuracy (trueness and precision) of measurement methods and results. Part 6: use in practice of accuracy values. 1994.Google Scholar

  • 41.

    Logue FC, Fraser WD, O’Reilly DS, Beastall GH. The circadian rhythm of intact parathyroid hormone (1-84) and nephrogenous cyclic adenosine monophosphate in normal men. J Endocrinol 1989;121:R1–3.CrossrefGoogle Scholar

  • 42.

    Statland BE, Winkel P, Bokelund H. Factors contributing to intra-individual variation of serum constituents. 2. Effects of exercise and diet on variation of serum constituents in healthy subjects. Clin Chem 1973;19:1380–3.PubMedGoogle Scholar

  • 43.

    Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM, et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 2013;98:2734–41.CrossrefPubMedGoogle Scholar

  • 44.

    Touvier M, Deschasaux M, Montourcy M, Sutton A, Charnaux N, Kesse-Guyot E, et al. Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocrinol Metab 2014;99:1196–203.CrossrefGoogle Scholar

  • 45.

    Eastell R, Arnold A, Brandi ML, Brown EM, D’Amour P, Hanley DA, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:340–50.PubMedCrossrefGoogle Scholar

  • 46.

    Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561–9.PubMedCrossrefGoogle Scholar

  • 47.

    Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, et al. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 2001;86:3086–90.PubMedGoogle Scholar

  • 48.

    Souberbielle JC, Fayol V, Sault C, Lawson-Body E, Kahan A, Cormier C. Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin Chem 2005;51:395–400.CrossrefGoogle Scholar

  • 49.

    Cavalier E, Delanaye P, Vranken L, Bekaert AC, Carlisi A, Chapelle JP, et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2012;27:1950–6.PubMedCrossrefGoogle Scholar

  • 50.

    Djennane M, Lebbah S, Roux C, Djoudi H, Cavalier E, Souberbielle JC. Vitamin D status of schoolchildren in Northern Algeria, seasonal variations and determinants of vitamin D deficiency. Osteoporos Int 2014;25:1493–502.PubMedCrossrefGoogle Scholar

  • 51.

    Souberbielle JC, Lawson-Body E, Hammadi B, Sarfati E, Kahan A, Cormier C. The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab 2003;88:3501–4.CrossrefPubMedGoogle Scholar

  • 52.

    Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results – a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 2011;26:3440–5.PubMedCrossrefGoogle Scholar

  • 53.

    Almond A, Ellis AR, Walker SW. Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann Clin Biochem 2012;49:63–7.CrossrefPubMedGoogle Scholar

  • 54.

    Cavalier E, Delanaye P, Lukas P, Carlisi A, Gadisseur R, Souberbielle JC. Standardization of DiaSorin and Roche automated third generation PTH assays with an International Standard: impact on clinical populations. Clin Chem Lab Med 2014;52:1137–41.PubMedCrossrefGoogle Scholar

  • 55.

    Kumar V, Barnidge DR, Chen LS, Twentyman JM, Cradic KW, Grebe SK, et al. Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin Chem 2010;56:306–13.PubMedCrossrefGoogle Scholar

About the article

Corresponding author: Prof. Etienne Cavalier, Department of Clinical Chemistry, University of Liège, CHU Sart-Tilman, 4000 Liège, Belgium, Phone: +32 4 3667692, Fax: +32 4 3667691, E-mail:


Received: 2015-04-01

Accepted: 2015-05-04

Published Online: 2015-06-02

Published in Print: 2015-11-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 53, Issue 12, Pages 1913–1919, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2015-0314.

Export Citation

©2015 by De Gruyter.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Huimin Chen, Xiaxia Han, Ying Cui, Yangfan Ye, Yogendranath Purrunsing, and Ningning Wang
BioMed Research International, 2018, Volume 2018, Page 1
[2]
Pragya Sharma-Ghimire, Zhaojing Chen, Vanessa Sherk, Michael Bemben, and Debra Bemben
Journal of Bone and Mineral Metabolism, 2018
[3]
Catharine M Sturgeon, Stuart Sprague, Alison Almond, Etienne Cavalier, William D Fraser, Alicia Algeciras-Schimnich, Ravinder Singh, Jean-Claude Souberbielle, and Hubert W. Vesper
Clinica Chimica Acta, 2017, Volume 467, Page 42

Comments (0)

Please log in or register to comment.
Log in